Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Optimism

Stock Track03-28

Immatics N.V. (NASDAQ: IMTX) stock is soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst support. The biotechnology company significantly outperformed expectations, marking a turnaround to profitability and substantial revenue growth.

Immatics reported a remarkable 189% increase in revenue, reaching €155.8 million for the full year 2024. The company swung to a net income of €15.2 million, a significant improvement from the €97.0 million loss recorded in the previous year. Earnings per share (EPS) came in at €0.14, compared to a loss of €1.20 in 2023. Both revenue and earnings surpassed analyst estimates, with revenue exceeding expectations by 39%.

Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. While the company's revenue is forecast to remain flat over the next three years, compared to the 20% growth projected for the US Biotechs industry, the strong financial performance and ongoing analyst confidence appear to be driving investor optimism. However, investors should note that the company's shares are down 11% from a week ago, suggesting some volatility in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153611799?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-28 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153611799","market":"hk","top_or_hot":-1,"title":"Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Optimism","media":"Stock Track","content":"<p>Immatics N.V. (NASDAQ: IMTX) stock is soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst support. The biotechnology company significantly outperformed expectations, marking a turnaround to profitability and substantial revenue growth.</p>\n\n<p>Immatics reported a remarkable 189% increase in revenue, reaching €155.8 million for the full year 2024. The company swung to a net income of €15.2 million, a significant improvement from the €97.0 million loss recorded in the previous year. Earnings per share (EPS) came in at €0.14, compared to a loss of €1.20 in 2023. Both revenue and earnings surpassed analyst estimates, with revenue exceeding expectations by 39%.</p>\n\n<p>Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. While the company's revenue is forecast to remain flat over the next three years, compared to the 20% growth projected for the US Biotechs industry, the strong financial performance and ongoing analyst confidence appear to be driving investor optimism. However, investors should note that the company's shares are down 11% from a week ago, suggesting some volatility in recent trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-28 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immatics N.V. (NASDAQ: IMTX) stock is soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst support. The biotechnology company significantly outperformed expectations, marking a turnaround to profitability and substantial revenue growth.</p>\n\n<p>Immatics reported a remarkable 189% increase in revenue, reaching €155.8 million for the full year 2024. The company swung to a net income of €15.2 million, a significant improvement from the €97.0 million loss recorded in the previous year. Earnings per share (EPS) came in at €0.14, compared to a loss of €1.20 in 2023. Both revenue and earnings surpassed analyst estimates, with revenue exceeding expectations by 39%.</p>\n\n<p>Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. While the company's revenue is forecast to remain flat over the next three years, compared to the 20% growth projected for the US Biotechs industry, the strong financial performance and ongoing analyst confidence appear to be driving investor optimism. However, investors should note that the company's shares are down 11% from a week ago, suggesting some volatility in recent trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1153611799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153611799","pubTimestamp":1743169105,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immatics N.V.  stock is soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst support. The biotechnology company significantly outperformed expectations, marking a turnaround to profitability and substantial revenue growth.Immatics reported a remarkable 189% increase in revenue, reaching 155.8 million for the full year 2024. The company swung to a net income of 15.2 million, a significant improvement from the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"由于2024年强劲业绩和分析师乐观情绪，股票跟踪Immatics N.V.盘前飙升5.72%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMTX":1},"content_text":"Immatics N.V. (NASDAQ: IMTX) stock is soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst support. The biotechnology company significantly outperformed expectations, marking a turnaround to profitability and substantial revenue growth.\nImmatics reported a remarkable 189% increase in revenue, reaching €155.8 million for the full year 2024. The company swung to a net income of €15.2 million, a significant improvement from the €97.0 million loss recorded in the previous year. Earnings per share (EPS) came in at €0.14, compared to a loss of €1.20 in 2023. Both revenue and earnings surpassed analyst estimates, with revenue exceeding expectations by 39%.\nAdding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. While the company's revenue is forecast to remain flat over the next three years, compared to the 20% growth projected for the US Biotechs industry, the strong financial performance and ongoing analyst confidence appear to be driving investor optimism. However, investors should note that the company's shares are down 11% from a week ago, suggesting some volatility in recent trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153611799"}